{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06321575",
            "orgStudyIdInfo": {
                "id": "AVA-CL-5000"
            },
            "organization": {
                "fullName": "Avantec Vascular",
                "class": "INDUSTRY"
            },
            "briefTitle": "The Golazo\u00ae Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)",
            "officialTitle": "The Golazo\u00ae Peripheral Atherectomy System for a Safe and Effective Atherectomy",
            "acronym": "GREAT",
            "therapeuticArea": [
                "Other"
            ],
            "study": "the-golazo-peripheral-atherectomy-system-for-a-safe-and-effective-atherectomy-great-trial"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-14",
            "studyFirstSubmitQcDate": "2024-03-14",
            "studyFirstPostDateStruct": {
                "date": "2024-03-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Avantec Vascular",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Bright Research Partners",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Yale Cardiovascular Research Group",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "The objective of this study is to establish reasonable assurance of safety and effectiveness of the Golazo\u00ae Peripheral Atherectomy System when used as indicated in 159 subjects with symptomatic infrainguinal peripheral arterial disease (PAD) in up to 15 investigational sites in the U.S.",
            "detailedDescription": "The investigation is a prospective, multicenter, non-randomized, single-arm, open-label pivotal clinical study. Subjects will undergo atherectomy treatment with the Golazo\u00ae Peripheral Atherectomy System and will then be followed 6-months post-procedure."
        },
        "conditionsModule": {
            "conditions": [
                "Peripheral Arterial Disease"
            ],
            "keywords": [
                "Symptomatic Infrainguinal Peripheral Arterial Disease",
                "Endovascular Intervention"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "The investigation is a prospective, multicenter, non-randomized, single-arm, open-label pivotal clinical study.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 159,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Golazo\u00ae Peripheral Atherectomy System",
                    "type": "EXPERIMENTAL",
                    "description": "Treatment atherectomy of the peripheral vasculature with the Golazo\u00ae Peripheral Atherectomy System.",
                    "interventionNames": [
                        "Device: Golazo\u00ae Peripheral Atherectomy System (Golazo\u00ae Peripheral AS)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Golazo\u00ae Peripheral Atherectomy System (Golazo\u00ae Peripheral AS)",
                    "description": "Golazo\u00ae Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo\u00ae Accustrike atherectomy catheter, and 2) the Golazo\u00ae motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.",
                    "armGroupLabels": [
                        "Golazo\u00ae Peripheral Atherectomy System"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Freedom from major adverse events (MAE)",
                    "description": "MAE is defined as:\n\n* Clinically-driven target lesion revascularization (CD-TLR)\n* Cardiovascular-related deaths\n* Unplanned major target limb amputation (above the ankle)\n* Perforations or dissections grade C or greater in the target vessel that require intervention\n* Symptomatic distal emboli requiring intervention\n* Pseudoaneurysm requiring intervention",
                    "timeFrame": "Index procedure through 30-day follow-up"
                },
                {
                    "measure": "Technical success",
                    "description": "Defined as the percent of target lesions that have a residual diameter stenosis \u226450% after atherectomy with the Golazo Peripheral AS and prior to adjunctive therapy",
                    "timeFrame": "During surgery/procedure"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in % stenosis in target lesion after treatment with Golazo Peripheral AS",
                    "description": "Determined after atherectomy and prior to other adjunctive therapies",
                    "timeFrame": "During surgery/procedure"
                },
                {
                    "measure": "Procedural Success Rate",
                    "description": "Defined as the proportion of the target lesion in which the final stenosis is \u226430% after treatment with atherectomy and any other adjunctive therapy",
                    "timeFrame": "End of surgery/procedure"
                },
                {
                    "measure": "Clinical Success Rate",
                    "description": "Defined as the proportion of subjects who have procedural success in all target lesions with at least one grade of improvement in the Rutherford clinical classification",
                    "timeFrame": "30-day and 6-month follow-up"
                },
                {
                    "measure": "Rates of all adverse events classified as MAEs",
                    "description": "As adjudicated by the CEC and presented by seriousness and causality (procedure and device relatedness)",
                    "timeFrame": "30-day and 6-month follow-up"
                },
                {
                    "measure": "Incidence of minor target limb amputation",
                    "description": "As adjudicated by the CEC",
                    "timeFrame": "30-day and 6-month follow-up"
                },
                {
                    "measure": "Incidence of myocardial infarction",
                    "description": "As adjudicated by the CEC",
                    "timeFrame": "30-day and 6-month follow-up"
                },
                {
                    "measure": "Incidence of target vessel revascularization (TVR) in the target limb",
                    "description": "As adjudicated by the CEC",
                    "timeFrame": "30-day and 6-month follow-up"
                },
                {
                    "measure": "Incidence of angiographic procedural distal embolization in the target limb",
                    "description": "As reported by the angiographic core laboratory",
                    "timeFrame": "During surgery/procedure"
                },
                {
                    "measure": "Time to primary patency of the target lesion(s)",
                    "description": "Primary patency is the interval from the time of the index procedure until the time of any intervention designed to maintain or reestablish patency of the target vessels, the time significant stenosis or total occlusion is confirmed, or the time of measurement of patency. Determined by duplex ultrasound/doppler (DUS) or angiography.",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Time to assisted primary patency of the target lesion(s)",
                    "description": "Assisted primary patency is the interval from the time of the index procedure until the time significant stenosis is confirmed, including interventions designed to maintain patency of a vessel with significant stenosis, the time total occlusion is confirmed, or the time of measurement of patency. Determined by duplex ultrasound/doppler (DUS) or angiography.",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Time to secondary patency of the target lesion(s)",
                    "description": "Secondary patency is the interval from the time of the index procedure until the time total occlusion is confirmed in a target vessel, including interventions designed to reestablish patency in a total occluded vessel, or the time of measurement of patency. Determined by duplex ultrasound/doppler (DUS) or angiography.",
                    "timeFrame": "6 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "General inclusion criteria:\n\n1. Age \u226518 years\n2. Candidate for atherectomy of the peripheral vasculature in the lower limbs\n3. Life expectancy \\>1 year in the opinion of the investigator\n4. Either of the following objective hemodynamic criteria:\n\n   1. Resting ankle brachial index (ABI) \u22640.90, or \u22640.75 after exercise\n   2. Subjects with non-compressible arteries (ABI \\>1.1) with a toe brachial index (TBI) \u22640.80\n5. Target limb Rutherford clinical classification category 3 to 5\n6. Suitable candidate for angiography and endovascular intervention in the opinion of the investigator\n7. Willing and able to comply with the protocol-specified procedures and assessments\n8. Informed consent granted\n\n   Angiographic inclusion criteria:\n9. Target lesion(s) defined as stenosis \u226570% by angiographic visual estimation\n10. Total treated lesion length \u226415 cm by angiographic visual estimation\n11. Target reference vessel diameter \u22652.0 mm and \u22644.5 mm by angiographic visual estimation\n12. Target lesion will have the potential of at least one patent tibial vessel runoff to the foot that crosses the ankle and provides perfusion at baseline\n\nGeneral exclusion criteria:\n\n1. Active infection in the target limb\n2. History of an endovascular procedure or open vascular surgery on the target limb within the last 30 days\n3. Planned surgical or interventional procedure within 30 days after the index procedure\n4. Lesion in the contralateral limb requiring intervention during the index procedure or within next 30 days\n5. Critical limb ischemia (CLI) with Rutherford clinical classification category 6\n6. Significant acute or chronic kidney disease with a GFR \\<30 and/or requiring dialysis\n7. Acute myocardial infarction (non-ST-elevation myocardial infarction or ST-segment elevation myocardial infarction) or other uncontrolled comorbidity in the opinion of the investigator\n8. Myocardial infarction (MI) or stroke within two months of baseline evaluation\n9. Pregnant or lactating\n10. Subject is participating in another clinical investigation of a device, drug, or procedure that has not completed the study treatment or that clinically interferes with the endpoints of this study (post-approval registries are allowed as long as the investigator determines there is no clinical interference with study endpoints)\n11. Contraindication to antiplatelet, anticoagulant, or thrombolytic therapy\n12. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count \\<125,000/microliter, known coagulopathy, or international normalized ratio (INR) \\>1.5\n13. Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately medicated\n14. History of heparin-induced thrombocytopenia (HIT)\n15. Any thrombolytic therapy within two weeks of enrollment\n16. Target lesion(s) within a native vessel graft or synthetic graft\n17. Significant stenosis or occlusion of inflow not successfully treated before the index procedure\n18. Any evidence or history of intracranial or gastrointestinal bleeding or intracranial aneurysm\n19. Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults)\n20. One or more of the following complications of the foot:\n\n    1. Osteomyelitis that extends to the metatarsal bones.\n    2. Gangrene involving the plantar skin of the forefoot, midfoot or heel\n    3. Deep ulcer or large shallow ulcer (\\>3cm) involving the plantar skin of the forefoot, midfoot, or heel\n    4. Any heel ulcer with/without calcaneal involvement\n    5. Any wound with calcaneal bone involvement\n    6. Wounds that are deemed to be neuropathic or non-ischemic in nature\n    7. Wounds that require flap coverage or complete wound management for large soft tissue defect\n21. Congestive heart failure with a NYHA functional classification of III or higher\n\n    Angiographic exclusion criteria:\n22. More than 2 lesions to be treated with the investigational device; lesions located within 3 mm may be considered a single lesion\n23. Clinical/angiographic complication (other than non-flow limiting dissections) attributed to a currently marketed device prior to introduction of the investigational device\n24. In-stent restenosis within the target lesion(s)\n25. Potentially unstable or flow-limiting dissection, type C or greater\n26. Clinical/angiographic evidence of distal embolization\n27. Inability to cross the proximal lesion vessel lumen with a guidewire (not subintimal)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gene Reu",
                    "role": "CONTACT",
                    "phone": "858-945-0007",
                    "email": "GReu@avantecvascular.com"
                },
                {
                    "name": "Rebecca Koller Zickert",
                    "role": "CONTACT",
                    "phone": "612-345-4544",
                    "email": "rebecca@brightresearchpartners.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Matthew Finn, MD",
                    "affiliation": "Cardiovascular Institute of the South",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Craig Walker, MD",
                    "affiliation": "Cardiovascular Institute of the South",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "First Coast Cardiovascular Institute",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32256",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amy Suphachinda",
                            "role": "CONTACT",
                            "phone": "904-493-3333",
                            "email": "asuphachinda@firstcoastcardio.com"
                        },
                        {
                            "name": "Vaqar Ali, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Yazan Khatib, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Radiology and Imaging Specialists of Lakeland",
                    "status": "RECRUITING",
                    "city": "Lakeland",
                    "state": "Florida",
                    "zip": "33801",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Eve Johnson",
                            "role": "CONTACT",
                            "email": "ejohnson@risimaging.com"
                        },
                        {
                            "name": "Ben Smith",
                            "role": "CONTACT",
                            "phone": "863-577-0296",
                            "phoneExt": "656",
                            "email": "Bsmith03@risimaging.com"
                        },
                        {
                            "name": "Lawrence Whitney, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.03947,
                        "lon": -81.9498
                    }
                },
                {
                    "facility": "Amavita Research Services",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33137",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nereisy Alonso",
                            "role": "CONTACT",
                            "phone": "786-537-4559",
                            "email": "researchadmin@amavita.health"
                        },
                        {
                            "name": "Yasnaya Cruz-Santiago",
                            "role": "CONTACT",
                            "email": "ycruz@research.amavita.health"
                        },
                        {
                            "name": "Pedro Martinez-Clark, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Cardiovascular Consultants of South Georgia",
                    "status": "RECRUITING",
                    "city": "Thomasville",
                    "state": "Georgia",
                    "zip": "31792",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lenore Beckett, RN",
                            "role": "CONTACT",
                            "email": "lenorebeckett@ccsgheart.com"
                        },
                        {
                            "name": "Lauren Montgomery",
                            "role": "CONTACT",
                            "phone": "229-584-5575"
                        },
                        {
                            "name": "B. Clay Sizemore, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.83658,
                        "lon": -83.97878
                    }
                },
                {
                    "facility": "Cardiovascular Institute of the South - Houma",
                    "status": "RECRUITING",
                    "city": "Houma",
                    "state": "Louisiana",
                    "zip": "70360",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Deanna Benoit",
                            "role": "CONTACT",
                            "email": "Deanna.Benoit@cardio.com"
                        },
                        {
                            "name": "Darla Patrick",
                            "role": "CONTACT",
                            "email": "darla.patrick@cardio.com"
                        },
                        {
                            "name": "Matthew Finn, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.59577,
                        "lon": -90.71953
                    }
                },
                {
                    "facility": "Vascular Breakthroughs",
                    "status": "RECRUITING",
                    "city": "Plymouth",
                    "state": "Massachusetts",
                    "zip": "02360",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elizabeth Gagne",
                            "role": "CONTACT",
                            "phone": "203-548-7860"
                        },
                        {
                            "name": "Maria Myslinski",
                            "role": "CONTACT",
                            "phone": "203-548-7860"
                        },
                        {
                            "name": "Scott James, DO",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.95844,
                        "lon": -70.66726
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000058729",
                    "term": "Peripheral Arterial Disease"
                },
                {
                    "id": "D000016491",
                    "term": "Peripheral Vascular Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000050197",
                    "term": "Atherosclerosis"
                },
                {
                    "id": "D000001161",
                    "term": "Arteriosclerosis"
                },
                {
                    "id": "D000001157",
                    "term": "Arterial Occlusive Diseases"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M29213",
                    "name": "Peripheral Arterial Disease",
                    "asFound": "Peripheral Arterial Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18894",
                    "name": "Peripheral Vascular Diseases",
                    "asFound": "Peripheral Arterial Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M26188",
                    "name": "Atherosclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4469",
                    "name": "Arteriosclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4465",
                    "name": "Arterial Occlusive Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}